Teva on the acquisition trail in Japan's growing generics sector?
This article was originally published in Scrip
Executive Summary
Hot on the heels of its planned $6.8 billion acquisition of Cephalon, Teva Pharmaceutical Industries may be pursuing a much smaller but nevertheless important deal aimed at bolstering its position in Japan's growing generics market.